Send to

Choose Destination
See comment in PubMed Commons below
Anadolu Kardiyol Derg. 2013 Jun;13(4):379-84. doi: 10.5152/akd.2013.109. Epub 2013 Apr 11.

Anticoagulation for non-valvular atrial fibrillation: new anticoagulant agents.

Author information

Department of Cardiology, Faculty of Medicine, Marmara University, İstanbul-Turkey.


in English, Turkish

Atrial fibrillation (AF) is a common cardiac arrhythmia and it is associated with systemic thromboembolism. Until recently, vitamin K antagonists (VKA) such as warfarin were the only available oral anticoagulant therapy for prevention of stroke and systemic embolism in AF. Limitations of VKA therapy have prompted researchers to search for novel anticoagulant drugs, which do not necessitate coagulation monitoring due to their more predictable pharmacokinetic profile. Large-scale phase III trials have been completed for some of these drugs and 'U.S. Food and Drug Administration (FDA)' approved dabigatran and rivaroxaban for prevention of systemic embolism in non-valvular AF patients. In this review, we will first focus on pharmacodynamic and pharmacokinetic profiles of these medications and then try to overview clinical trial results. We will also try to mention the current controversies regarding the clinical application of these drugs.

[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Kare Publishing
    Loading ...
    Support Center